Amer Zeidan, MBBS, discusses the recent expansion of the indication for luspatercept-amt to the frontline setting to treat anemia in patients with lower-risk myelodysplastic syndromes.
Amer Zeidan, MBBS, associate professor of internal medicine (Hematology), chief of hematologic malignancies and director of early therapeutics research for Hematology, and leader of the clinical research team for leukemias and myeloid malignancies at the Yale Cancer Center, discusses the data that led to the approval of luspatercept-amt (Reblozyl) to treat anemia in patients with myelodysplastic syndromes (MDS).
The initial approval for luspatercept was for certain adults with MDS who progressed on an erythropoiesis-stimulating agent (ESA) and needed 2 or more red blood cell (RBC) units over 8 weeks. These patients included those patients with very low- to intermediate-risk MDS with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with RS and thrombocytosis. This approval was based off the MEDALIST trial (NCT02631070), which met its primary end point of more patients being RBC-transfusion independent with luspatercept (37.9%) compared with those on placebo (24.6%).
Further research on the randomized phase 3 COMMANDS trial (NCT03682536) led to the expansion of the indication of luspatercept to the frontline setting for patients with anemia and lower-risk MDS. Zeidan discusses the rationale and design of the study, as well as how the use of luspatercept approximately doubled the proportion of patients who were RBC-transfusion independent compared with those patients on ESAs.
TRANSCRIPTION:
0:08 | Based on this, the COMMANDS trial was conducted, which tried to answer 2 questions. The first question was, what is the efficacy in the frontline setting against ESAs? And then the second question was about activity outside of the ring sideroblast setting. So, the COMMANDS study was a large international study, and actually, it was a positive study for the primary and many of the secondary end points. So, the main finding of COMMANDS was improvement in the rate of transfusion independence, which were for 12 weeks combined with a mean hemoglobin rise of 1.5 g/dL.
0:30 | This [occurred in] 60% with luspatercept compared to 30% with ESA, and based on this, the FDA has approved luspatercept also in the frontline setting for anemic patients who have anemia and who may require blood cell transfusions.
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More